United Kingdom Active Pharmaceutical Ingredients (API) Market Insights Forecasts to 2033

• The Market Size is Growing at a CAGR of 6.01% from 2023 to 2033
• The U.K. Active Pharmaceutical Ingredients (API) Market Size is Expected To reach significant Share by 2033

The United Kingdom Active Pharmaceutical Ingredients (API) Market Size is anticipated to Exceed significant Share by 2033, Growing at a CAGR of 6.01% from 2023 to 2033. The growing prevalence of chronic disorders, the geriatric population, and expanding sophistication in oncology drug research are driving the growth of the active pharmaceutical ingredients (API) market in the United Kingdom.     

Market Overview

An active pharmaceutical ingredient (API) is defined as “any substance or substances that are intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient in the drug product.”  API is a pharmacologically active component in medicine responsible for the treatment, mitigation, prevention, cure, or diagnosis of diseases and is present with other components made up of inert ingredients, which generally have no pharmacological effects. APIs are produced by processing chemical compounds. Thus, are responsible for the pharmaceutical effect of formulated pharmaceuticals (medicines). They are produced using highly technological industrial processes, both during R&D and commercial production phases. The United Kingdom, in Western Europe, is one of the countries that has a concentrated demand for active pharmaceutical ingredients, essentially related to the higher proportion of sales of generic drugs in these countries. There is rising demand for more quality and more reliability from API sources to avoid public health risks.   

Report Coverage

This research report categorizes the market for the UK active pharmaceutical ingredients (API) market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Active Pharmaceutical Ingredients (API) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the active pharmaceutical ingredients (API) market.

Driving Factors

There is a growing investment in R&D for API production processes, as well as in quality, environment, and safety, resulting in better, safer, and cleaner technologies and a substantial increase in pharmaceutical technology. The increasing prevalence of infectious, genetic, cardiovascular, and other chronic disorders as well as the growing geriatric population, the rising prevalence of cancer, and the expanding sophistication in oncology drug research are all these factors are contributing drive the market demand for active pharmaceutical ingredients. One of the most common illnesses in the region is diabetic. Thus, the high diabetic population in the country raises the company’s focus on creating innovative, safe medications that need a lot of API for drug formulation, which fuels the market expansion. Further, the rising focus on developing high-quality APIs by key market players are anticipated to fuel the market growth.

Restraining Factors

The stringent regulations for drug approvals and various drug price policies in the country are hindering market growth.

Market Segmentation

The United Kingdom Active Pharmaceutical Ingredients (API) Market share is classified into drug type and application.

• The branded segment is expected to hold a significant share of the United Kingdom active pharmaceutical ingredients (API) market during the forecast period.   

The United Kingdom active pharmaceutical ingredients (API) market is segmented by drug type into generic and branded. Among these, the branded segment is expected to hold a significant share of the United Kingdom active pharmaceutical ingredients (API) market during the forecast period. The proven safety and efficacy of branded drugs is responsible for consumer trusts for about receiving the best possible treatment. The increasing company activities in developing drugs and increasing product launched in the country. The increasing demand for ophthalmic drugs and solution owing to the high prevalence of eye surgeries propelling the market demand.      

• The oncology segment is anticipated to grow at the fastest CAGR rate during the forecast period.

The United Kingdom active pharmaceutical ingredients (API) market is segmented by application into cardiology, oncology, pulmonology, neurology, orthopaedic, ophthalmology, and others. Among these, the oncology segment is anticipated to grow at the fastest CAGR rate during the forecast period. As per statistics published by Breast Cancer Now, 55,000 women are diagnosed with breast cancer in the United Kingdom every year. The increasing prevalence of cancer in the region surges the need for developing drugs for the treatment is anticipated to propel the market demand. Country’s growing efforts to raise cancer awareness and increase funding for therapeutic development are anticipated to augment the market growth of active pharmaceutical ingredients.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the UK active pharmaceutical ingredients (API) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• Novartis AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• BASF SE
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Aurobindo Pharma
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• AbbVie, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In August 2022, Piramal Pharma Solutions has expanded and upgraded UK facilities. The expansions and upgrades represent a total investment of approximately 55 million in the company’s UK-based drug development and manufacturing capabilities as well as new employment opportunities for technical and operational staff.

• In August 2022, Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO) announced a 1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates facility.

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United Kingdom Active Pharmaceutical Ingredients (API) Market based on the below-mentioned segments:

United Kingdom Active Pharmaceutical Ingredients (API) Market, By Drug Type

• Generic
• Branded

United Kingdom Active Pharmaceutical Ingredients (API) Market, By Application

• Cardiology
• Oncology
• Pulmonology
• Neurology
• Orthopaedic
• Ophthalmology
• Others